Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | The development of novel treatment modalities: regulations and expectations

Saar Gill • 5 Oct 2017
ESH 2017
General

Novel technologies have the potential to allow us to treat more ailments, but often come at the price of new toxicities. Speaking from the International Conference of Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH), Saar Gill, MD, PhD from the University of Pennsylvania, Philadelphia, PA discusses how stronger regulations and greater transparency between scientists, patients and physicians has impacted these new technologies. Dr Gill also highlights the necessity of controlling side effects and the importance of managing expectations.

More from Saar Gill

Immunotherapeutics in AML
Immunotherapeutics in AML
Amer Zeidan et al. • 29 Sep 2022
Translational insights into T-cell engagers and CAR T-cell therapy: targets, the microbiome, & more
11:47
Translational insights into T-cell engagers and CAR T-cell therapy: targets, the microbiome, & more
Ciara Freeman et al. • 12 Apr 2025
An update on CAR-T in CLL
An update on CAR-T in CLL
Saar Gill et al. • 29 May 2024
Exploring the potential of CAR-T therapy in CLL
16:12
Exploring the potential of CAR-T therapy in CLL
John Gribben et al. • 30 Apr 2022

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals